{"analyses":[{"ciLowerLimit":"0.6","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.2","groupIds":["OG000","OG001"],"nonInferiorityType":"OTHER","pValue":"0.3296","paramType":"Hazard Ratio (HR)","paramValue":"0.8","statisticalMethod":"Regression, Cox"}],"classes":[{"categories":[{"measurements":[{"comment":"Upper limit not calculated due to insufficient number of events.","groupId":"OG000","lowerLimit":"166.1","upperLimit":"NA","value":"263.1"},{"comment":"Upper limit not calculated due to insufficient number of events.","groupId":"OG001","lowerLimit":"173.7","upperLimit":"NA","value":"229.1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"135"},{"groupId":"OG001","value":"132"}],"units":"Participants"}],"description":"Progression free survival (PFS) is defined as the time from the date of first dose of maintenance therapy to the date of the first objective documentation of tumor progression or death due to any cause. Analysis was based on Kaplan Meier estimates. The PFS events were determined using a modification of the IWG 1999 criteria.","dispersionType":"95% Confidence Interval","groups":[{"description":"Maintenance Period (18 Cycles): lenalidomide 10 mg once daily on Days 1 to 21 of every 28-day Cycle for Cycles 13 to 30 AND rituximab 375 mg/m2 on Day 1 of every 28-day Cycle for Cycles 13, 15, 17, 19, 21, 23, 25, 27, and 29. Followed by Optional Maintenance Period (up to PD): Lenalidomide 10 mg once daily on Days 1 to 21 of every 28-day Cycle up to PD. This treatment will be at the discretion of the participant and the investigator.","id":"OG000","title":"Arm A: Lenalidomide + Rituximab"},{"description":"Maintenance Period (18 Cycles): participants received rituximab 375 mg/m2 on Day 1 of every 28-day Cycle for Cycles 13, 15, 17, 19, 21, 23, 25, 27, and 29","id":"OG001","title":"Arm B: Rituximab"}],"paramType":"MEDIAN","populationDescription":"All randomized participants in Arm A and Arm B, as prespecified in the protocol","reportingStatus":"POSTED","timeFrame":"From the first dose date of maintenance therapy to objective disease progression or death from any cause, whichever occurs first (up to approximately 432 weeks)","title":"Progression Free Survival (PFS)","type":"PRIMARY","unitOfMeasure":"Weeks"}